Project Grant R43HL176386
Award Date
8/20/24
Completion Date
7/31/25
Dollars Obligated
$289K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Blacksburg, VA, USA
Similar Awards
This Project Grant award for $355,935 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) supports the development of a novel, oral immunoregulatory therapeutic for the treatment of asthma. The primary objectives are to characterize the therapeutic efficacy and dosing regimen of the compound in mouse models of asthma, and to evaluate its ability to modulate immune function and suppress inflammation in human...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Biotherapeutics, Inc. provides $347,608 to develop a novel, oral, once-daily immunoregulatory therapeutic for the treatment of asthma. The key objectives are to: 1) Characterize the therapeutic efficacy and route of administration of the drug candidate in mouse models of asthma, and 2) Determine the translational ability of the therapeutic candidate in human primary cells...
The federal Project Grant award R01HL173055, totaling $834,840.00, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program. The grant supports research at Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System Incorporated, to emulate hypothetical randomized and adaptive trials to establish the comparative effectiveness of biologic therapies for patients with severe, uncontrolled asthma. The...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $300,000 to Parmedics, Inc., a for-profit, woman-owned biotechnology company, for the development of small molecule protease-activated receptor-2 (PAR2) antagonists as potential oral therapeutics for asthma. The goal is to characterize two novel PAR2 antagonists, C937 and C938, with improved pharmacodynamics and pharmacokinetics to enable...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $636,843 to The Regents of the University of California, San Francisco to conduct research aimed at characterizing a targetable stromal factor that alters immune cell accumulation in the lung and defines the downstream effects of these immune cells on airway epithelial cells. The research project, titled "Targeting the Stromal Niche for...
This Project Grant award of $387,116 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research at the University of South Florida to investigate the mechanisms underlying house dust mite-induced airway hyperreactivity, a key symptom of asthma. The research aims to define the specific sensory nerve populations and signaling pathways triggered by house dust mite exposure that lead to the development of airway hyperreactivity, in order to...
This federal Project Grant award, valued at $154,861 and provided by the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research), aims to advance the integration of social and medical care to promote health equity among children with asthma. The key products and services to be delivered under this grant include: Developing a population-based machine learning model to predict risk of asthma-related hospitalization among children in Washington, D.C. using social...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $863,328 to Aquillius Corp to develop a wearable graphene respiratory sensor for early detection and monitoring of asthma. The sensor will utilize graphene nanotechnology to provide real-time, continuous monitoring and measurement of pulmonary functions, which aims to improve patient monitoring, treatment, and diagnosis of asthma. The project will first optimize the...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $604,750 to Scientific Horizons Consulting LLC to develop a novel inhalation device prototype for the pulmonary delivery of anti-inflammatory agents to the distal airways of patients with chronic obstructive pulmonary disease (COPD). The key products and services to be delivered include: Investigating the feasibility of aerosolizing and delivering...
This $177,403 Project Grant was awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program. The funding supports research to disentangle the heterogeneity of asthma, identify distinct asthma endotypes, and investigate biological mechanisms underlying established risk factors. The project will utilize multi-omics data from three cohorts of asthmatic children to analyze the interplay between genetic, epigenetic, and metabolomic...